FindTrial
Sign In

Active monitoring and key drug varieties risk prediction and intervention in inpatients with drug induced hypofibrinogenemia

Active monitoring and key drug varieties risk prediction and intervention in inpatients with drug induced hypofibrinogenemia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400086456
Enrollment
Unknown
Registered
2024-07-02
Start date
2024-09-01
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

drug induced hypofibrinogenemia

Interventions

Case group:None (Retrospective observational study)
Control group:None (Retrospective observational study)
Experiment group:For patients with high risk of drug-induced hypofibrinogenemia, clinical pharmacists give individualized medication recommendations for key varieties.

Sponsors

Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: (1) Fibrinogen = 2.0 g/L before treatment and fibrinogen < 2.0 g/L after treatment; (2) Age=18 years.

Exclusion criteria

Exclusion criteria: (1) Baseline fibrinogen < 2.0 g/L; (2) lack of fibrinogen levels before or after treatment within 15 days; (3) lack of hospital medical record information; (3) Patients in hematology department or combined other diseases that may cause hypofibrinogenemia, including congenital or acquired coagulopathy, blood system diseases (DIC), etc.

Design outcomes

Primary

MeasureTime frame
Fibrinogen;—

Secondary

MeasureTime frame
Blood indices (blood routine, blood biochemistry, coagulation);—

Countries

China

Contacts

Public ContactZhu Man

Chinese PLA General Hospital

zhucindy301@189.cn+86 189 0102 0608

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026